Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China

Tang, Jianxin1,2; Weng, Ruihui3; Fang, Taishi1,2; Zhang, Kangjun1,2; Yan, Xu1,2; Jin, Xin1,2; Xie, Linjie1,2; Zhao, Dong1,2

2024-04-08

10.1186/s12879-024-09284-2

BMC INFECTIOUS DISEASES   影响因子和分区

1471-2334

Background Highly active antiretroviral therapy (HAART) has been able to improve the immune system function and survival of human immunodeficiency virus (HIV) patients. However, Patients coinfected with HIV and hepatitis B virus (HBV) are more likely to develop end-stage liver disease (ESLD) than those infected with HBV alone. Consequently, liver transplantation is often required for these patients. This study evaluates the outcomes of orthotopic liver transplantation (OLT) of HIV-HBV coinfected patients in China. Methods We conducted a retrospective analysis on all HIV-HBV coinfected patients that underwent OLT from April 1, 2019 to December 31, 2021 and their outcomes were compared to all HBV monoinfected patients undergoing OLT during the same period. Patient outcomes were determined, including cumulative survival, viral load, CD4 T-cell count and postoperative complications. Results The median follow-up of HIV recipients was 36 months after OLT (interquartile range 12-39 months). Almost all patients had stable CD4 T-cell count (> 200 copies/ul), undetectable HBV DNA levels, and undetectable HIV RNA load during follow-up. The 1-, 2-, and 3-year posttransplant survival rates were 85.7% for the HIV group (unchanged from 1 to 3 years) versus 82.2%, 81.2%, and 78.8% for the non-HIV group. Cumulative survival among HIV-HBV coinfected recipients was not significantly different from the HBV monoinfected recipients (log-rank test P = 0.692). The percentage of deaths attributed to infection was comparable between the HIV and non-HIV groups (14.3% vs. 9.32%, P = 0.665). Post OLT, there was no significant difference in acute rejection, cytomegalovirus infection, bacteremia, pulmonary infection, acute kidney injury, de novo tumor and vascular and biliary complications. Conclusions Liver transplantation in patients with HIV-HBV coinfection yields excellent outcomes in terms of intermediate- or long-term survival rate and low incidence of postoperative complications in China. These findings suggest that OLT is safe and feasible for HIV-HBV coinfected patients with ESLD. Trial registration Chinese Clinical Trial Registry (ChiCTR2300067631), registered 11 January 2023.

Human immunodeficiency virus Hepatitis B virus End-stage liver disease Liver transplantation China

SCI

英语

第一 ; 通讯

Infectious Diseases

Infectious Diseases

WOS:001198694500005

BMC

IMMUNOLOGY

Web of Science

1.Southern Univ Sci & Technol, Affiliated Hosp 2, Shenzhen Peoples Hosp 3, Natl Clin Res Ctr Infect Dis,Dept Liver Surg, Longgang Dist,Bulan Rd 29, Shenzhen 518000, Peoples R China
2.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Affiliated Hosp 2, Natl Clin Res Ctr Infect Dis,Organ Transplantat Ct, Longgang Dist,Bulan Rd 29, Shenzhen 518000, Peoples R China
3.Univ Sci & Technol, Affiliated Hosp Southern 2, Shenzhen Peoples Hosp 3, Dept Neurol, Shenzhen 518000, Peoples R China

Tang, Jianxin,Weng, Ruihui,Fang, Taishi,et al. Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China[J]. BMC INFECTIOUS DISEASES,2024,24(1).

Tang, Jianxin.,Weng, Ruihui.,Fang, Taishi.,Zhang, Kangjun.,Yan, Xu.,...&Zhao, Dong.(2024).Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China.BMC INFECTIOUS DISEASES,24(1).

Tang, Jianxin,et al."Clinical outcomes of liver transplantation in human immunodeficiency virus/hepatitis B virus coinfected patients in China".BMC INFECTIOUS DISEASES 24.1(2024).